|
1
|
Ministry of Health: National Cancer
Registry of Poland: Reports based on data of National Cancer
Registry of Poland. (updated 19-11-2010). http://epid.coi.waw.pl/krn/english/index.asp.
Accessed June 30, 2012.
|
|
2
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Doll A, Abal M, Rigau M, Monge M, Gonzalez
M, Demajo S, Colás E, Llauradó M, Alazzouzi H, Planagumá J, et al:
Novel molecular profiles of endometrial cancer-new light through
old windows. J Steroid Biochem Mol Biol. 108:221–229. 2008.
View Article : Google Scholar
|
|
4
|
Ryan AJ, Susil B, Jobling TW and Oehler
MK: Endometrial cancer. Cell Tissue Res. 322:53–61. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
O'Hara AJ and Bell DW: The genomics and
genetics of endometrial cancer. Adv Genomics Genet. 2012:33–47.
2012.PubMed/NCBI
|
|
6
|
Okuda T, Sekizawa A, Purwosunu Y,
Nagatsuka M, Morioka M, Hayashi M and Okai T: Genetics of
endometrial cancers. Obstet Gynecol Int. 2010:9840132010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Merritt MA and Cramer DW: Molecular
pathogenesis of endometrial and ovarian cancer. Cancer Biomark.
9:287–305. 2010.
|
|
8
|
Ferguson BW, Gao X, Zelazowski MJ, Lee J,
Jeter CR, Abba MC and Aldaz CM: The cancer gene WWOX behaves as an
inhibitor of SMAD3 transcriptional activity via direct binding. BMC
Cancer. 13:5932013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kurek KC, Del Mare S, Salah Z, Abdeen S,
Sadiq H, Lee SH, Gaudio E, Zanesi N, Jones KB, DeYoung B, et al:
Frequent attenuation of the WWOX tumor suppressor in osteosarcoma
is associated with increased tumorigenicity and aberrant RUNX2
expression. Cancer Res. 70:5577–5586. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gaudio E, Palamarchuk A, Palumbo T,
Trapasso F, Pekarsky Y, Croce CM and Aqeilan RI: Physical
association with WWOX suppresses c-Jun transcriptional activity.
Cancer Res. 66:11585–11589. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aqeilan RI, Pekarsky Y, Herrero JJ,
Palamarchuk A, Letofsky J, Druck T, Trapasso F, Han SY, Melino G,
Huebner K, et al: Functional association between Wwox tumor
suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci USA.
101:4401–4406. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aqeilan RI, Palamarchuk A, Weigel RJ,
Herrero JJ, Pekarsky Y and Croce CM: Physical and functional
interactions between the Wwox tumor suppressor protein and the
AP-2gamma transcription factor. Cancer Res. 64:8256–8261. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aqeilan RI, Donati V, Palamarchuk A,
Trapasso F, Kaou M, Pekarsky Y, Sudol M and Croce CM: WW
domain-containing proteins, WWOX and YAP, compete for interaction
with ErbB-4 and modulate its transcriptional function. Cancer Res.
65:6764–6772. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aqeilan RI, Donati V, Gaudio E, Nicoloso
MS, Sundvall M, Korhonen A, Lundin J, Isola J, Sudol M, Joensuu H,
et al: Association of Wwox with ErbB4 in breast cancer. Cancer Res.
67:9330–9336. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Abu-Remaileh M and Aqeilan RI: Tumor
suppressor WWOX regulates glucose metabolism via HIF1α modulation.
Cell Death Differ. 21:1805–1814. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aqeilan RI and Croce CM: WWOX in
biological control and tumorigenesis. J Cell Physiol. 212:307–310.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aqeilan RI, Hagan JP, de Bruin A, Rawahneh
M, Salah Z, Gaudio E, Siddiqui H, Volinia S, Alder H, Lian JB, et
al: Targeted ablation of the WW domain-containing oxidoreductase
tumor suppressor leads to impaired steroidogenesis. Endocrinology.
150:1530–1535. 2009. View Article : Google Scholar :
|
|
18
|
Bednarek AK, Laflin KJ, Daniel RL, Liao Q,
Hawkins KA and Aldaz CM: WWOX, a novel WW domain-containing protein
mapping to human chromosome 16q23.3-24.1, a region frequently
affected in breast cancer. Cancer Res. 60:2140–2145.
2000.PubMed/NCBI
|
|
19
|
Lan C, Chenggang W, Yulan B, Xiaohui D,
Junhui Z and Xiao W: Aberrant expression of WWOX protein in
epithelial ovarian cancer: A clinicopathologic and
immunohistochemical study. Int J Gynecol Pathol. 31:125–132. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qin HR, Iliopoulos D, Nakamura T,
Costinean S, Volinia S, Druck T, Sun J, Okumura H and Huebner K:
Wwox suppresses prostate cancer cell growth through modulation of
ErbB2-mediated androgen receptor signaling. Mol Cancer Res.
5:957–965. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Płuciennik E, Kusińska R, Potemski P,
Kubiak R, Kordek R and Bednarek AK: WWOX--the FRA16D cancer gene:
Expression correlation with breast cancer progression and
prognosis. Eur J Surg Oncol. 32:153–157. 2006. View Article : Google Scholar
|
|
22
|
Płuciennik E, Kośla K, Wójcik-Krowiranda
K, Bieńkiewicz A and Bednarek AK: The WWOX tumor suppressor gene in
endometrial adenocarcinoma. Int J Mol Med. 32:1458–1464. 2013.
|
|
23
|
Cui Z, Lin D, Cheng F, Luo L, Kong L, Xu
J, Hu J and Lan F: The role of the WWOX gene in leukemia and its
mechanisms of action. Oncol Rep. 29:2154–2162. 2013.PubMed/NCBI
|
|
24
|
Ishii H, Vecchione A, Furukawa Y,
Sutheesophon K, Han SY, Druck T, Kuroki T, Trapasso F, Nishimura M,
Saito Y, et al: Expression of FRA16D/WWOX and FRA3B/FHIT genes in
hematopoietic malignancies. Mol Cancer Res. 1:940–947.
2003.PubMed/NCBI
|
|
25
|
Liu SY, Chiang MF and Chen YJ: Role of WW
domain proteins WWOX in development, prognosis, and treatment
response of glioma. Exp Biol Med (Maywood). 240:315–323. 2015.
View Article : Google Scholar
|
|
26
|
Nowakowska M, Pospiech K, Lewandowska U,
Piastowska-Ciesielska AW and Bednarek AK: Diverse effect of WWOX
overexpression in HT29 and SW480 colon cancer cell lines. Tumour
Biol. 35:9291–9301. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xie B, Zen Q, Wang X, He X, Xie Y, Zhang Z
and Li H: ACK1 promotes hepatocellular carcinoma progression via
downregulating WWOX and activating AKT signaling. Int J Oncol.
46:2057–2066. 2015.PubMed/NCBI
|
|
28
|
Yan H and Sun Y: Evaluation of the
mechanism of epithelial-mesenchymal transition in human ovarian
cancer stem cells transfected with a WW domain-containing
oxidoreductase gene. Oncol Lett. 8:426–430. 2014.PubMed/NCBI
|
|
29
|
Płuciennik E, Nowakowska M, Pospiech K,
Stępień A, Wołkowicz M, Gałdyszyńska M, Popęda M, Wójcik-Krowiranda
K, Bieńkiewicz A and Bednarek AK: The role of WWOX tumor suppressor
gene in the regulation of EMT process via regulation of
CDH1-ZEB1-VIM expression in endometrial cancer. Int J Oncol.
46:2639–2648. 2015.
|
|
30
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group-wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aqeilan RI, Kuroki T, Pekarsky Y, Albagha
O, Trapasso F, Baffa R, Huebner K, Edmonds P and Croce CM: Loss of
WWOX expression in gastric carcinoma. Clin Cancer Res.
10:3053–3058. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nunez MI, Rosen DG, Ludes-Meyers JH, Abba
MC, Kil H, Page R, Klein-Szanto AJ, Godwin AK, Liu J, Mills GB, et
al: WWOX protein expression varies among ovarian carcinoma
histotypes and correlates with less favorable outcome. BMC Cancer.
5:642005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qu J, Lu W, Li B, Lu C and Wan X: WWOX
induces apoptosis and inhibits proliferation in cervical cancer and
cell lines. Int J Mol Med. 31:1139–1147. 2013.PubMed/NCBI
|
|
34
|
Bednarek AK, Keck-Waggoner CL, Daniel RL,
Laflin KJ, Bergsagel PL, Kiguchi K, Brenner AJ and Aldaz CM: WWOX,
the FRA16D gene, behaves as a suppressor of tumor growth. Cancer
Res. 61:8068–8073. 2001.PubMed/NCBI
|
|
35
|
Nunez MI, Ludes-Meyers J, Abba MC, Kil H,
Abbey NW, Page RE, Sahin A, Klein-Szanto AJ and Aldaz CM: Frequent
loss of WWOX expression in breast cancer: Correlation with estrogen
receptor status. Breast Cancer Res Treat. 89:99–105. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Göthlin Eremo A, Wegman P, Stål O,
Nordenskjöld B, Fornander T and Wingren S: Wwox expression may
predict benefit from adjuvant tamoxifen in randomized breast cancer
patients. Oncol Rep. 29:1467–1474. 2013.PubMed/NCBI
|
|
37
|
Schwenke M, Knöfler M, Velicky P, Weimar
CH, Kruse M, Samalecos A, Wolf A, Macklon NS, Bamberger AM and
Gellersen B: Control of human endometrial stromal cell motility by
PDGF-BB, HB-EGF and trophoblast-secreted factors. PLoS One.
8:e543362013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View Article : Google Scholar
|
|
39
|
Li X, Regezi J, Ross FP, Blystone S, Ilić
D, Leong SP and Ramos DM: Integrin alphavbeta3 mediates K1735
murine melanoma cell motility in vivo and in vitro. J Cell Sci.
114:2665–2672. 2001.PubMed/NCBI
|
|
40
|
Abdeen SK, Salah Z, Khawaled S and Aqeilan
RI: Characterization of WWOX inactivation in murine mammary gland
development. J Cell Physiol. 228:1391–1396. 2013. View Article : Google Scholar
|
|
41
|
Gourley C, Paige AJ, Taylor KJ, Ward C,
Kuske B, Zhang J, Sun M, Janczar S, Harrison DJ, Muir M, et al:
WWOX gene expression abolishes ovarian cancer tumorigenicity in
vivo and decreases attachment to fibronectin via integrin α3.
Cancer Res. 69:4835–4842. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang JQ, Li L, Song HL, Paige A and Gabra
H: Effect of WWOX gene on the attachment and adhesion of ovarian
cancer cells. Zhonghua Fu Chan Ke Za Zhi. 44:529–532. 2009.In
Chinese. PubMed/NCBI
|
|
43
|
Palumbo JS and Degen JL: Fibrinogen and
tumor cell metastasis. Haemostasis. 31(Suppl 1): S11–S15. 2001.
|
|
44
|
Lessey BA, Castelbaum AJ, Buck CA, Lei Y,
Yowell CW and Sun J: Further characterization of endometrial
integrins during the menstrual cycle and in pregnancy. Fertil
Steril. 62:497–506. 1994.PubMed/NCBI
|
|
45
|
Rebhun RB, Cheng H, Gershenwald JE, Fan D,
Fidler IJ and Langley RR: Constitutive expression of the alpha4
integrin correlates with tumorigenicity and lymph node metastasis
of the B16 murine melanoma. Neoplasia. 12:173–182. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Holzmann B1, Gosslar U and Bittner M:
Alpha 4 integrins and tumor metastasis. Curr Top Microbiol Immunol.
231:125–141. 1998.PubMed/NCBI
|
|
47
|
Jin H, Aiyer A, Su J, Borgstrom P, Stupack
D, Friedlander M and Varner J: A homing mechanism for bone
marrow-derived progenitor cell recruitment to the neovasculature. J
Clin Invest. 116:652–662. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Garmy-Susini B, Jin H, Zhu Y, Sung RJ,
Hwang R and Varner J: Integrin α4β1-VCAM-1-mediated adhesion
between endothelial and mural cells is required for blood vessel
maturation. J Clin Invest. 115:1542–1551. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Prifti S, Zourab Y, Koumouridis A,
Bohlmann M, Strowitzki T and Rabe T: Role of integrins in invasion
of endometrial cancer cell lines. Gynecol Oncol. 84:12–20. 2002.
View Article : Google Scholar
|
|
50
|
Lessey BA, Albelda S, Buck CA, Castelbaum
AJ, Yeh I, Kohler M and Berchuck A: Distribution of integrin cell
adhesion molecules in endometrial cancer. Am J Pathol. 146:717–726.
1995.PubMed/NCBI
|
|
51
|
Lewandowska U, Żelazowski M, Seta K,
Byczewska M, Płuciennik E and Bednarek AK: WWOX, the tumour
suppressor gene affected in multiple cancer. J Physiol Pharmacol.
60(Suppl 1): 47–56. 2009.
|
|
52
|
Martin TA and Jiang WG: Loss of tight
junction barrier function and its role in cancer metastasis.
Biochim Biophys Acta. 1788:872–891. 2009. View Article : Google Scholar
|
|
53
|
Neuzillet C, Tijeras-Raballand A, Cros J,
Faivre S, Hammel P and Raymond E: Stromal expression of SPARC in
pancreatic adenocarcinoma. Cancer Metastasis Rev. 32:585–602. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yusuf N, Inagaki T, Kusunoki S, Okabe H,
Yamada I, Matsumoto A, Terao Y, Takeda S and Kato K: SPARC was
overexpressed in human endometrial cancer stem-like cells and
promoted migration activity. Gynecol Oncol. 134:356–363. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Köbel M, Langhammer T, Hüttelmaier S,
Schmitt WD, Kriese K, Dittmer J, Strauss HG, Thomssen C and
Hauptmann S: Ezrin expression is related to poor prognosis in FIGO
stage I endometrioid carcinomas. Mod Pathol. 19:581–587. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ohtani K, Sakamoto H, Rutherford T, Chen
Z, Kikuchi A, Yamamoto T, Satoh K and Naftolin F: Ezrin, a
membrane-cytoskeletal linking protein, is highly expressed in
atypical endometrial hyperplasia and uterine endometrioid
adenocarcinoma. Cancer Lett. 179:79–86. 2002. View Article : Google Scholar : PubMed/NCBI
|
